{"id":52293,"date":"2021-04-05T12:39:00","date_gmt":"2021-04-05T12:39:00","guid":{"rendered":"https:\/\/www.verificat.cat\/cansino-work\/"},"modified":"2021-04-05T12:39:00","modified_gmt":"2021-04-05T12:39:00","slug":"cansino-work","status":"publish","type":"post","link":"https:\/\/www.verificat.cat\/en\/cansino-work\/","title":{"rendered":"CanSino"},"content":{"rendered":"<p><br \/>\n<\/p>\n<p>Chinese vaccine company <a href=\"http:\/\/www.cansinotech.com\/\" target=\"_blank\" rel=\"noopener\">CanSinoBio<\/a> has developed the vaccine CanSino using a <a href=\"http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/654.html\" target=\"_blank\" rel=\"noopener\">viral vector<\/a>. This method uses a <a href=\"https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/different-vaccines\/viralvector.html\" target=\"_blank\" rel=\"noopener\">vector<\/a>, i.e. a different virus from SARS-CoV-2, to enter a cell and infect it. In this way, it uses the cellular machinery to produce the spike protein, present in this coronavirus, to generate antibodies.<\/p>\n<p>In May and July 2020, the manufacturers published the results of <a href=\"http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/580.html\" target=\"_blank\" rel=\"noopener\">phases I<\/a> and <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31605-6\/fulltext\" target=\"_blank\" rel=\"noopener\">II<\/a> of their clinical trial in the British scientific journal The Lancet. In early November last year, they announced the start of phase III trial in <a href=\"http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/580.html\" target=\"_blank\" rel=\"noopener\">Mexico<\/a>, where they estimated to recruit 15,000 volunteers. By then it had already completed two other phase III trials in <a href=\"http:\/\/www.cansinotech.com\/html\/1\/\/\/179\/180\/580.html\" target=\"_blank\" rel=\"noopener\">Russia and Pakistan<\/a>. They have also been carried out in <a href=\"https:\/\/covid19.trackvaccines.org\/vaccines\/2\/\" target=\"_blank\" rel=\"noopener\">Argentina and Chile<\/a>. In total, <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04526990\" target=\"_blank\" rel=\"noopener\">40.000 volunteers<\/a> participated in this phase, which showed an <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2021-02-08\/pakistan-says-cansino-s-covid-vaccine-shows-65-7-efficacy#:~:text=CanSino%20Biologics%20Inc.&#039;s%20experimental,growing%20arsenal%20against%20Covid%2D19.\" target=\"_blank\" rel=\"noopener\">efficacy of 65,7%<\/a>.<\/p>\n<p>The CanSino vaccine is administered <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04526990\" target=\"_blank\" rel=\"noopener\">in a single dose<\/a> and, in addition to <a href=\"https:\/\/covid19.trackvaccines.org\/vaccines\/2\/\" target=\"_blank\" rel=\"noopener\">China, Mexico, Hungary and Pakistan have authorised its use<\/a>.<\/p>\n<p>The <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31208-3\/fulltext\" target=\"_blank\" rel=\"noopener\">most commonly reported side effects<\/a> in the clinical trials are pain at the injection site, headache, fever and tiredness. No severe reactions have been reported.<\/p>\n<p><a href=\"https:\/\/www.melingbiomedical.com\/en\/about-us\/news\/0220.html\" target=\"_blank\" rel=\"noopener\">CanSino vaccine<\/a> can be stored between 2&ordm;C and 8&ordm;C, although the manufacturer has not specified for how long.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chinese vaccine company CanSinoBio has developed the vaccine CanSino using  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[169],"tags":[208],"class_list":["post-52293","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-vaccines-en","vc-legacy-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/comments?post=52293"}],"version-history":[{"count":0,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/media?parent=52293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/categories?post=52293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/tags?post=52293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}